First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Abstract

Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).

Keywords

Affiliated Institutions

• Lehigh Valley Health Network US
• Juravinski Cancer Centre CA
• The Netherlands Cancer Institute NL
• University Hospital Heidelberg DE
• University of Groningen NL
• The University of Texas MD Anderson Cancer Center US
• Hospital Universitario 12 De Octubre ES
• Duke University US
• University Medical Center Groningen NL
• Hospital Universitario Insular de Gran Canaria ES
• Santa Maria Nuova Hospital IT
• University of Pittsburgh Medical Center US
• Bristol-Myers Squibb (United States) US
• Hebron University PS
• Central Baptist Hospital US
• Moffitt Cancer Center US
• The Ohio State University US
• Fox Chase Cancer Center US
• Institute of Oncology Prof. Dr. Ion Chiricuta RO
• Fakultní nemocnice Bulovka CZ
• Vanderbilt University Medical Center US
• Heidelberg University DE
• MUSC Hollings Cancer Center US
• LungenClinic Grosshansdorf DE
• University of Lausanne CH
• German Center for Lung Research DE

Related Publications